Polygenic Embryo Screening: Where Do We Stand? – ESHRE
European Society of Human Reproduction and Embryology (ESHRE) shared a post on LinkedIn:
“Polygenic Embryo Screening: Where Do We Stand?
Polygenic embryo screening (PES) can now assess IVF embryos for risks of heart disease, diabetes, schizophrenia and cancers. It’s already available, but highly controversial.
The disconnect: patients show strong interest – healthcare professionals have serious concerns.
Join this ESHRE webinar as international experts share new research on these diverging attitudes. Through focused presentations and panel discussion, we’ll explore:
- What drives patient demand vs. professional hesitation
- How views differ across cultures and demographics
- The implications for policy, education and patient care
Be part of shaping how we navigate this emerging frontier in hashtag#ReproductiveGenetics.
Date: 10 February 2026 | 17:00 CET
Find out more.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Mar 3, 2026, 00:23Final Call for Review of Updated ESHRE IVF Laboratory Recommendations – ESHRE
-
Mar 3, 2026, 00:15Abstract Submissions Are Now Open for ASM 2026! – BSGI
-
Mar 2, 2026, 14:06Ever Wondered How Ovulation Works? Let’s Break It Down! – Fertility Plus
-
Mar 2, 2026, 13:48Join RBMO Webinar on Global Declining Fertility Rates – RBMO
-
Mar 2, 2026, 13:39Governance of Polygenic Embryo Screening – Fertility and Sterility
-
Mar 2, 2026, 13:26AJOG MFM February 2026 Podcast Episode Is Out!
-
Mar 2, 2026, 13:21Yousef Zakharia Leads Clinical Research Aimed at Genitourinary Cancers – Mayo Clinic
-
Mar 1, 2026, 16:41Exploring Frozen and Fresh Embryo Transfer Risks – Fertility and Sterility
-
Mar 1, 2026, 16:40Foraviset Welcomes Prof. Tasuku Harada to Advisory Board – Foraviset